Profiling of lapatinib- and neratinib-resistant HER2+ breast cancer cell lines showed that a TKI resistance phenotype in vitro is associated with reduced trastuzumab-related ADCC, which can also be independent of HER2 expression levels [97,98]. This evidence concerns the gene ERBB2 and breast carcinoma.